Form 4: Kezar Life Sciences Merger: Insider Option Changes

Mark C. Schiller's Form 4 details the cancellation and conversion of his stock options following Kezar Life Sciences' merger with Aurinia Pharma.

Summary

• This filing is a Form 4, reporting changes in beneficial ownership for Mark C. Schiller, Chief Operating Officer of Kezar Life Sciences, Inc.
• The transactions occurred on May 11, 2026, in connection with the merger of Kezar Life Sciences with Aurinia Pharma U.S., Inc.
• Schiller's stock options were either cancelled or converted into cash and contingent value rights (CVRs) based on their exercise price relative to the merger's cash consideration of $6.955 per share.
• Options with an exercise price equal to or greater than $6.955 were cancelled with no consideration.
• Options with an exercise price less than $6.955 were converted into a cash payment and one CVR per share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details the mechanics of stock option conversion and cancellation due to a merger, rather than new operational or financial performance.

Positives

• Mark C. Schiller's 'in-the-money' stock options were converted into cash and contingent value rights, providing him with value from the merger.
• The merger itself represents a significant event for the company and its stakeholders, potentially offering a return on investment.

Negatives

• Mark C. Schiller's 'out-of-the-money' stock options were cancelled with no consideration, resulting in a loss of potential value for those specific options.

Risks

• The value of the Contingent Value Rights (CVRs) is dependent on the achievement of specified milestones, introducing uncertainty regarding future payouts.
• The merger agreement details complex terms for option conversion and CVR payouts, which could lead to disputes or misunderstandings.

Future Outlook

The future outlook for the contingent value rights (CVRs) is dependent on the achievement of specified milestones as outlined in the CVR Agreement.

Industry Context

StockSavvy.ai notes that this Form 4 filing is typical in the biotechnology and pharmaceutical sectors during merger and acquisition activities, where executive compensation structures involving stock options are common and subject to specific treatment upon a change of control.

Stakeholder Impact

• Shareholders: Those who tendered shares received cash and CVRs, with the CVR value contingent on future milestones. Those who did not tender may have different outcomes based on the merger's surviving entity status.
• Management (Mark C. Schiller): Experienced a conversion of 'in-the-money' options to cash and CVRs, while 'out-of-the-money' options were cancelled without compensation.
• Employees: Other employees holding stock options would have experienced similar conversions or cancellations based on the terms of the merger agreement.

Next Steps

• Achievement of specified milestones to trigger payments under the Contingent Value Rights (CVRs).
• Potential future reporting related to the CVR payouts if milestones are met.

Key Dates

Keywords

Form 4, Kezar Life Sciences, Aurinia Pharma, Merger, Stock Options, Insider Trading, Beneficial Ownership, Contingent Value Rights, Mark C. Schiller, SEC Filing